ArticleFrontiers in immunology2020
Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- SSTR2 receptor states and cellular metabolism modulateEANM innovation · 2026Article
- B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think.Kidney medicine · 2026Article
- Obinutuzumab in kidney transplantation: Past, present, and future.World journal of transplantation · 2025Review
- Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESI.Nature communications · 2025Article
- Article
- Review
- Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue.Scientific reports · 2023Article
- Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology.Cureus · 2023Review
- Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.Drugs · 2023Review
- Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Complement C5 is a novel biomarker for liver metastasis of colorectal cancer.Journal of gastrointestinal oncology · 2022Article
- Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.BMC cancer · 2022Article
- CD47-SIRPα-targeted therapeutics: status and prospects.Immuno-oncology technology · 2022Review
- Rituximab combined with GDP regimen can effectively improve the efficacy and immune function of non-Hodgkin lymphoma.American journal of translational research · 2022Article
- Antibody-mediated cell depletion therapies in multiple sclerosis.Frontiers in immunology · 2022Review
- Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.Frontiers in immunology · 2022Article
- Solution structures of human myeloma IgG3 antibody reveal extended Fab and Fc regions relative to the other IgG subclasses.The Journal of biological chemistry · 2021Article
- Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.Molecular therapy oncolytics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Monoclonal antibodies directed against the CD20 surface antigen on B cells are widely used in the therapy of B cell malignancies. Upon administration, the antibodies bind to CD20 expressing B cells and induce their depletion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.